Charles Schwab Investment Management Inc. Acquires 7,138 Shares of ASP Isotopes Inc. $ASPI

Charles Schwab Investment Management Inc. lifted its position in ASP Isotopes Inc. (NASDAQ:ASPI) by 4.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 165,364 shares of the company’s stock after buying an additional 7,138 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.22% of ASP Isotopes worth $776,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. AWM Investment Company Inc. increased its position in shares of ASP Isotopes by 16.0% during the fourth quarter. AWM Investment Company Inc. now owns 4,246,186 shares of the company’s stock valued at $19,235,000 after buying an additional 586,600 shares during the period. Two Sigma Investments LP purchased a new position in shares of ASP Isotopes during the fourth quarter valued at about $1,980,000. Northern Trust Corp increased its position in shares of ASP Isotopes by 15.5% during the fourth quarter. Northern Trust Corp now owns 435,688 shares of the company’s stock valued at $1,974,000 after buying an additional 58,525 shares during the period. Nuveen Asset Management LLC increased its position in shares of ASP Isotopes by 672.1% during the fourth quarter. Nuveen Asset Management LLC now owns 413,346 shares of the company’s stock valued at $1,872,000 after buying an additional 359,811 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of ASP Isotopes by 13.0% during the first quarter. Bank of New York Mellon Corp now owns 142,257 shares of the company’s stock valued at $667,000 after buying an additional 16,383 shares during the period. 16.80% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group upped their target price on shares of ASP Isotopes from $8.50 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, May 21st. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $7.75.

ASP Isotopes Stock Performance

Shares of NASDAQ ASPI opened at $8.67 on Wednesday. The firm’s 50-day moving average price is $8.95 and its 200-day moving average price is $6.96. ASP Isotopes Inc. has a 52-week low of $2.11 and a 52-week high of $11.68. The company has a quick ratio of 14.56, a current ratio of 14.72 and a debt-to-equity ratio of 3.53. The company has a market cap of $796.86 million, a PE ratio of -14.21 and a beta of 3.35.

ASP Isotopes (NASDAQ:ASPI) last announced its earnings results on Thursday, August 14th. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.92). ASP Isotopes had a negative net margin of 2,181.62% and a negative return on equity of 239.22%. The business had revenue of $1.20 million for the quarter, compared to analysts’ expectations of $1.60 million. As a group, analysts anticipate that ASP Isotopes Inc. will post -0.24 EPS for the current year.

ASP Isotopes Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.